Aureon Biosciences Corporation

Aureon Biosciences, Inc. is responsible for designing and developing prognostic tests. It can facilitate predictive and personalized cancer treatment plans. The company's prognostic tests include Prostate Px, which can assist doctors in providing patients with possible treatment options, as well as the probability of disease recurrence and progression; and Post-Op Px, a prognostic test that provides patients and their doctors with information about treatment options. Its prognostic tools offer risk assessments both at diagnosis and after surgery.